Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intrathecal Administration of Dual Checkpoint Inhibitor in Combination With Pemetrexed in Patients With Leptomeningeal Metastasis: a Phase I/II Study

NCT06809530 is registered in ClinicalTrials.gov with Guangzhou Medical University as lead sponsor.

NCT NCT06809530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06809530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intrathecal Administration of Dual Checkpoint Inhibitor in Combination With Pemetrexed in Patients With Leptomeningeal Metastasis: a Phase I/II Study
Lead sponsor
Guangzhou Medical University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 17, 2025
Completion date
September 1, 2027
Enrollment
39 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

ctla4, leptomeningeal metastasis, pd-1 inhibitor, pemetrexed, solid tumors